Symbols / GRNA
GRNA Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
—
Low
—
High
—
Mean
—
- A temperature-sensitive CRISPR-Cas12a system for sterile insect technique - Nature Mon, 03 Nov 2025 08
- GreenLight Biosciences Holdings (NASDAQ:GRNA) shareholders have endured a 79% loss from investing in the stock a year ago - Yahoo Finance Wed, 06 Jul 2022 07
- CRISPR Market worth $5.47 billion by 2030 - MarketsandMarkets Wed, 14 May 2025 07
- SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of GreenLight Biosciences Holdings and Encourages Long-Term GRNA / ENVI Shareholders to Contact the Firm - PR Newswire hu, 15 Jun 2023 07
- Brief: Greenlight Biosciences completes $1.2bn merger to list on Nasdaq, closes up 5% - AgFunderNews Fri, 04 Feb 2022 08
- GreenLight Biosciences Holdings PBC Stock Price, News, Quote & History - Investing News Network hu, 13 Apr 2023 06
- GreenLight Biosciences Enters into Definitive Merger - GlobeNewswire ue, 30 May 2023 07
- Agilent's oligonucleotide expansion plan pulls down ST Pharm’s stock prices - koreabiomed.com Wed, 11 Jan 2023 08
- Heritable transgene-free genome editing in plants by grafting of wild-type shoots to transgenic donor rootstocks - Nature Mon, 02 Jan 2023 08
- Oligonucleotide CDMO Market Growth, Drivers, and Opportunities - MarketsandMarkets hu, 09 Jan 2025 12
- Double-tap gene drive uses iterative genome targeting to help overcome resistance alleles - Nature Mon, 09 May 2022 07
- Efficient in vivo labeling of endogenous proteins with SMART delineates retina cellular and synaptic organization - Nature ue, 22 Apr 2025 07
- CRISPR Market Growth, Drivers, and Opportunities - MarketsandMarkets Fri, 09 Nov 2018 15
- Construction of adenovirus vectors simultaneously expressing four multiplex, double-nicking guide RNAs of CRISPR/Cas9 and in vivo genome editing - Nature Wed, 17 Feb 2021 08
- An inducible CRISPR interference library for genetic interrogation of Saccharomyces cerevisiae biology - Nature Fri, 27 Nov 2020 08
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for GRNA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|